Old Drugs, New Signals: What the Side-Effect Conversation Is Really Saying
The side-effect conversation is getting louder—and it’s not just about safety.
For years, “new” drug stories have been told the same way: a novel mechanism, a pivotal trial, a c…

A drug patent isn’t “worth” what the market says—it’s worth what litigation lets you keep.
In pharma M&A, the headline number is usually the easy part: peak sales potential, probability-weighted cash flows, and the comforting math of discounted val…

Two clocks. One drug. And a deadline that can’t be negotiated.
In pharma, timelines aren’t just operational—they’re strategic. The difference between “we still have protection” and “competition is at the door” can come down to two clocks running at t…

Small Molecules vs. Biologics: The Real LEO Playbook for Generics and Biosimilars
The patent landscape isn’t just “more patents” or “fewer patents.” It’s different games—and the rules change depending on whether you’re defending a small-molecule franch…

Biopharma’s next revenue window isn’t in the lab—it’s in the tender.
Drug patent cliffs are no longer a distant threat. They’re a calendar event. And for commercial vendors in Europe—especially those supporting biosimilars, generics, and off-patent l…

Pharma’s biggest “new drug” play isn’t a new molecule—it’s a new claim.
For years, investors and executives have chased the next blockbuster compound. But a quieter engine has been quietly printing billions: taking an old molecule—one that’s already be…

Biopharma is entering a new kind of “cliff”—not just patent expiration, but the operational scramble that follows it.
When a drug loses exclusivity, the market doesn’t simply open. It floods. Generics arrive faster than many commercial teams can retool…

One-shot: How to pick the right drug patent for maximum term-extension value
In pharma, timing is everything—but so is which clock you’re trying to extend.
Drug patent term extensions (and related exclusivity add-ons) can represent real, measurable val…